Loading stock data…
Shattuck Labs (STTK)
$6.85+0.41 (+6.37%)
Market ClosedLast close Jun 29
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Shattuck Labs, Inc. in the Healthcare sector is trading at $6.85 with a market capitalization of $410M. Wall Street consensus targets $14.83 (6 analysts), implying a +116.5% move over the next 12 months. The stock is currently near its 52-week high of $8.33, remaining 60.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +116.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $1.00M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.54M↓ | -$13.37M↓ | -$10.72M↑ | -$13.03M↑ | -$14.39M |
| Net Income | -$14.77M↓ | -$12.59M↓ | -$10.06M↑ | -$12.46M↑ | -$13.70M |
Peer Comparison
JNJUNHPFE
Fundamentals
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monocl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$409.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.04%
Volume
Today's trading volume
2.04M
Recent News
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Shattuck Labs...
Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)
Shattuck Labs, Inc. (NASDAQ:STTK) is one of the best performing small cap stocks so far in 2026. Cantor Fitzgerald initiated coverage of Shattuck Labs, Inc. (NASDAQ:STTK) with an Overweight rating on April 27, telling investors in a research note that the stock’s more than 800% rise over the last 12 months points towards enthusiasm for its […]
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
Investors were pleased to hear that the company's lead pipeline drug is making tangible progress.
Why Shattuck Labs Stock Soared in December
Buttressed by a significant amount of fresh capital, the company is showing progress in the early development of its top investigational drug.
Several Insiders Invested In Shattuck Labs Flagging Positive News
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...